Jun 29, 2020 8:30 am EDT Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking
May 14, 2020 7:30 am EDT Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
May 5, 2020 8:00 am EDT Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020
Mar 13, 2020 8:00 am EDT Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020 5:30 am EDT Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Mar 3, 2020 5:30 am EST Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
Feb 6, 2020 8:00 am EST Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
Jan 13, 2020 6:30 am EST Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Dec 19, 2019 4:05 pm EST Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
